Midi-dysferlin Gene Therapy Vector for Muscle Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for dysferlinopathies, such as muscular dystrophies caused by dysferlin gene mutations, lack a curative treatment, and existing gene therapies do not effectively restore muscle cell membrane repair functions.
Innovation Solution
A nucleic acid sequence encoding for essential domains of dysferlin, including exon 40a, is used to develop a recombinant expression vector that codes for a polypeptide capable of restoring muscle cell membrane repair, protection, and vesicle trafficking, specifically through the calpain cleavage site, and a 'midi-dysferlin' protein is designed for gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of moving object
If a truncated dysferlin protein (mini-dysferlin or Nanodysferlin) is used for gene therapy, then the vector size is reduced and transduction efficiency is improved, but the protein may lack essential functional domains required for complete membrane repair function
Solution Approach 1:
The dysferlin protein is segmented into essential functional domains (C2A, C2B, C2F, C2G, and transmembrane domain) that are retained in the truncated version. This segmentation allows identification and preservation of critical regions responsible for membrane repair function while removing non-essential portions to reduce vector size.
Solution Approach 2:
Non-essential portions of the dysferlin protein sequence are extracted and removed to create a truncated version. The extraction process selectively eliminates regions that are not critical for membrane repair function, thereby reducing the overall protein size and corresponding vector size while maintaining therapeutic efficacy.
2Reliability
If exon 40a is included in the dysferlin construct, then calpain cleavage site function is restored improving membrane repair, but the protein sequence length and vector size increase
Solution Approach 1:
The exon 40a region is locally optimized to include only the essential calpain cleavage site sequence rather than the entire exon. This local quality adjustment ensures that the critical cleavage function is preserved while minimizing the added sequence length, allowing targeted inclusion of functional elements without unnecessary bulk.
3Reliability
If full-length dysferlin is used for gene therapy, then complete membrane repair function is achieved, but vector size exceeds delivery capacity limits
Solution Approach 1:
Instead of providing the complete full-length dysferlin protein, a partial version containing only the essential functional domains is delivered. This partial action approach provides sufficient therapeutic effect for membrane repair without the need for the entire protein sequence, thereby fitting within vector size constraints while maintaining reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution effectively reduces or prevents symptoms of dysferlinopathy by restoring muscle cell membrane repair and protein vesicle trafficking, as demonstrated by improved membrane repair and protection from mechanical stress in animal models.
Implementation Method 1
a nucleic acid sequence encoding for a polypeptide comprising a cleavage site by calpain
Data Source
AI summary
Gene therapy for treating dysferlinopathy. More particularly, a polynucleotide sequence including several domains of dysferlin, or functional variants thereof, and a viral vector for gene therapy including at least a polynucleotide sequence, which includes exon 40a of the coding sequence of dysferlin. Also, a pharmaceutical composition including the viral vector.